Goldman Sachs lowered the firm’s price target on iRhythm (IRTC) to $184 from $211 and keeps a Neutral rating on the shares.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on IRTC:
- iRhythm should be bought on subpoena weakness, says William Blair
- iRhythm says received civil investigative demand from DOJ in December
- iRhythm price target lowered to $215 from $240 at JPMorgan
- iRhythm price target lowered to $200 from $220 at Baird
- iRhythm price target lowered to $198 from $212 at Canaccord